Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 5/20 | 0.69 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | RHOC | P08134 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.69 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.67 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.63 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.63 |
| ▸ | PDE6D | O43924 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12073345 | 0.92 | HMGCR (0.72) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL14308682 | 0.90 | HMGCR (0.70) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL14318919 | 0.89 | HMGCR (0.69) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL5809239 | 0.89 | HMGCR (0.71) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL2546119 | 0.89 | HMGCR (0.66) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL12192335 | 0.89 | HMGCR (0.77) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL6469721 | 0.88 | HMGCR (0.68) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL5806847 | 0.88 | HMGCR (0.70) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL5809438 | 0.88 | HMGCR (0.70) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL19963503 | 0.88 | HMGCR (0.65) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169838-A1 | Novel class of compounds for the treatment of cardiovascular disease. | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2021-06-10 | — | — | US | disclosed |
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2019-02-07 | — | — | US | disclosed |
| US-20130178636-A1 | ESTERS OF HEXANOIC ACIDS AS INTERMEDIATES FOR THE PREPARATION OF ATORVASTATIN | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2013-07-11 | — | — | US | disclosed |
| US-20130178636-A1 | ESTERS OF HEXANOIC ACIDS AS INTERMEDIATES FOR THE PREPARATION OF ATORVASTATIN | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2013-07-11 | — | — | US | disclosed |
| US-8148550-B2 | selected from fluvastatin, rosuvastatin, cerivastatin, glenvastatin or atorvastatin, by reduction or lactonization of chemical intermediate compounds, then hydrogenation, decyclization and deprotection of hydroxy groups | RATIOPHARM GMBH (DE) | 2012-04-03 | — | — | US | disclosed |
| US-20110098314-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | ALCON, INC. (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7777056-B2 | Method for manufacture of 4-hydroxy pyran-2-one derivatives | LUPIN LTD. (IN) | 2010-08-17 | — | — | US | disclosed |
| US-7777056-B2 | Method for manufacture of 4-hydroxy pyran-2-one derivatives | LUPIN LTD. (IN) | 2010-08-17 | — | — | US | disclosed |
| US-20080269508-A1 | Method for Manufacture of 4-Hydroxy Pyran-2-One Derivatives | LUPIN LTD. (IN) | 2008-10-30 | — | — | US | disclosed |
| US-20080269508-A1 | Method for Manufacture of 4-Hydroxy Pyran-2-One Derivatives | LUPIN LTD. (IN) | 2008-10-30 | — | — | US | disclosed |
| US-20080249306-A1 | Method for the Production of Statins | RATIOPHARM GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | FABP3, TNNI3, TNNT2 | HMGCR 18/4885SLCO1B1 3158/4885ABCB11 753/4885 |
| US-20080269508-A1 | Method for Manufacture of 4-Hydroxy Pyran-2-One Derivatives | HPD, DHODH, OXGR1 | HMGCR 310/4885SLCO1B1 1782/4885ABCB11 3652/4885 |
| US-20130178636-A1 | ESTERS OF HEXANOIC ACIDS AS INTERMEDIATES FOR THE PREPARATION OF ATORVASTATIN | HMGCR, FFAR3, HSD17B12 | HMGCR 1/4885SLCO1B1 183/4885ABCB11 638/4885 |
| US-20210169838-A1 | Novel class of compounds for the treatment of cardiovascular disease. | FABP3, TNNI3, TNNT2 | HMGCR 16/4885SLCO1B1 3185/4885ABCB11 512/4885 |
| US-20080249306-A1 | Method for the Production of Statins | HMGCR, COASY, PCSK9 | HMGCR 1/4885SLCO1B1 898/4885ABCB11 743/4885 |
| US-20110098314-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | HMGCR, HMGB2, GRHPR | HMGCR 1/4885SLCO1B1 939/4885ABCB11 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.